BRL Medicine Inc., a cell and gene therapy (CGT) developer based in Shanghai, has reportedly raised over RMB 200 million (USD 28.3 million) in a Series B financing round. The round was led by Shanghai FTZ Fund, with participation from Oriental Fortune Capital, Tasly Capital, Betta Biomedical Industry Fund, and Gopher Asset Management. The proceeds will be used to accelerate translational research and the implementation of cell and gene therapies, as well as to support the firm’s global research and development (R&D) initiatives.
Company Profile and Pipeline
Founded in 2013, BRL Medicine is developing an autologous hematopoietic stem progenitor cell therapy for treating transfusion-dependent beta-thalassemia. The therapy entered a Phase I/II clinical study with investigational new drug (IND) approval in China in August of this year. Additionally, BRL’s “non-viral PD1 fixed-point chimeric antigen receptor (CAR)-T” program is expected to obtain IND status within this year, according to company sources.-Fineline Info & Tech
